Objective: To assess impact of direct acting antiviral (DAA) therapies for treatment of hepatitis C virus (HCV) genotypes 1,3 and 4 in a real-world cohort from India. Conclusions: DAA therapy for HCV genotypes 1, 3 and 4 achieves high SVR rates in all patients, including those with cirrhosis and previous non-responders.
INTRODUCTION
The introduction of oral combinations of direct acting antivirals (DAAs) has quickly changed the landscape of hepatitis C virus (HCV) treatment in last few years. Due to higher efficacy, safety and fewer side effects than interferon-based regimes, these DAAs have now become the standard of care for treatment of chronic HCV infection. [1] [2] [3] Various clinical trials have shown high rates of sustained virological response (SVR) after treatment with direct acting antivirals. In a phase 3 open label study involving treatment naïve genotype 1 patients with or without cirrhosis, combination therapy with sofosbuvir (SOF) and ledipasvir (LDV) with or without ribavirin (RBV) achieved SVR rates between 97-99%. ION-2 trial included genotype 1 patients who were treatment experienced and those with cirrhosis (20%) and SVR rates were 94% and 96% with SOF/LDV without and with ribavirin respectively. The SVR rates increased to 99% in both groups when treatment duration was increased to 24 M a n u s c r i p t weeks. 4 In patients with genotype 4, the SYNERGY trial showed SVR rates of 95%
with SOF/LDV and RBV.
5
Genotype 3 patients have been reported to have a relatively lower response rate with the DAAs. In a phase 3 trial ALLY-3, sofosbuvir (SOF) and daclatasvir (DCV) given without RBV in treatment naïve patients achieved SVR rates of 97% and 58% in non cirrhotic and cirrhotic patients respectively. In patients who were treatment experienced, SVR rates were 94% and 69% in non-cirrhotic and cirrhotic patients, respectively. 6 In the ALLY 3+ trial, treatment naïve and experienced patients with advanced fibrosis (METAVIR F3) and cirrhosis were treated with SOF, DCV and ribavirin (RBV) for 12 and 16 weeks. SVR rates in patients with advanced fibrosis were 100% both after 12 and 16 weeks of therapy, while in cirrhotics SVR rates were 83% and 88% with 12 and 16 week therapy respectively.
7
As the clinical trials are conducted in controlled settings, the results derived from these may not be generalizable to the real world settings. The efficacy of the drugs in a real world setting is influenced by several factors like drug compliance, adverse events leading to discontinuation and other factors like cost and availability of the drugs. The present study was done to assess the efficacy and safety of DAAs and assess the impact of therapy in a real world setting in the northern state of Punjab, India.
METHODS

Setting
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A c c e p t e d M a n u s c r i p t
This was a single center, prospective, observational study evaluating the treatment outcomes in a real-world cohort of patients with chronic HCV genotypes 1, 3 and 4 who were treated with DAAs between December 2015 to December 2016.
Patients and treatment
All patients diagnosed as chronic hepatitis C with or without cirrhosis, including those who were treatment naïve or previously exposed to interferon based regimens and were considered for all oral direct acting antiviral therapy were included in the present study. 
Efficacy assessment
The treatment efficacy was monitored at 4 weeks, at the end of therapy (12 or 24 weeks) and 12 weeks after the end of treatment for rapid virological response (RVR), end of treatment response (ETR) and sustained virological response (SVR) respectively. Non response was defined as failure to achieve ETR, breakthrough as reappearance of HCV RNA at any time during treatment after a negative result or increase of 1 log10 IU/ml from nadir and virological relapse as undetectable HCV RNA at the end of treatment, but failure to achieve SVR.
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Safety Assessment
Patients were followed up on regular intervals for any adverse events or abnormal findings on physical examination and clinical laboratory tests. For patients who were treated with ribavirin based regimes, haemoglobin was monitored according to the CTCAE (common terminology criteria for adverse events) and dose reduced by 200 mg each week if Hb was <10g/dl, till the value rose to 10g/dl or greater. RBV was withheld in patients with HB <8.5 g/dl. The dose of DAAs remained unchanged.
Statistical analysis
Patients were enrolled based on the clinical need for treatment and not the statistical considerations. The primary population for efficacy analysis [modified intention to treat (mITT)] included patients who started treatment and received at least one dose of the medicine and had no virological failure, those who were lost to follow up or had missing SVR data were excluded. In addition, efficacy was analysed based on intention to treat (ITT) population which included all patients who received atleast one dose of the planned regimen and had HCV RNA at 12 weeks post treatment (SVR 12), patients who were still on treatment at the time of analysis were excluded.
The data was analyzed using descriptive and inferential statistics. The measures of descriptive statistics used in this study were frequency and percentage distribution tables. Chi-square test was used as inferential statistics in the present study.
RESULTS
Baseline characteristics and demographics
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A c c e p t e d M a n u s c r i p t A total of 842 patients were diagnosed with HCV infection during the study period, of which 648 (77%) opted for treatment with DAAs ( Figure 1 ). The mean age was 43.7±14.1 years and a majority of patients were males (n=424, 65.4%), in the age group of 41-60 years (n=320, 49.4%). Forty eight patients (7.4%) were treatment experienced. Patients were most commonly infected with genotype 3 (n=467, 72.1%) and genotype 1 (n=145, 22.4%) and 49.7% (n=320) had high viral load. Several concurrent medical conditions were noted (Table 2) , and 25.6% of the patients had history of concurrent significant alcohol intake. History of intravenous drug abuse was noted in 51 (7.9%) of the patients. Cirrhosis was present in 271 patients (41.8%), and among them a majority (n=159, 58.7%) were compensated.
Hepatocellular carcinoma (HCC) was noted in 11 patients, all of whom were eligible for locoregional therapies and thus offered DAAs with intent of reducing liver related morbidity and mortality and preventing recurrence of HCC after treatment.
Coinfection with HBV was noted in 5 patients and three patients were post renal transplant recipients. A c c e p t e d M a n u s c r i p t cirrhotic patients when compared to those with cirrhosis (Table 3, Figure 2 ). As compared to the patients who were previously treated with interferon based regimes, treatment naïve patients had a higher SVR, though the difference was not statistically significant (Table 3 , Figure 2 ). SVR rates were 100% in patients with genotypes 1 and 4, irrespective of the liver status and history of previous treatment (Table 3 , Figure 2 ). SVR rates were similar among patients with low and high viral load, irrespective of the genotype.
Efficacy assessment
Treatment Failure
Virological failure was noted in 70 patients (2.8%). A majority of these (n=50) were the patients who were lost to follow up during or after treatment. Six patients had non response, 2 had breakthrough and 10 relapsed. Treatment failures were more commonly seen in genotype 3 (non response in 5, both patients with breakthrough and all 10 patients with relapse). Two patients died due to massive variceal bleed and intracranial bleed respectively. Among these, one patient had achieved ETR and the other died while on treatment, after achieving RVR.
Adverse Events
Though a few patients experienced minor side effects, none of them had to stop therapy due to drug intolerance or adverse events. The side effects like fatigue and anemia [seen in 53 patients (8.3%)] were more common in patients where ribavirin was added to the DAAs and improved with dose reduction.
DISCUSSION
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The introduction of DAAs has revolutionized the treatment of HCV infection over the last few years. Though various Phase-3 trials have reported high efficacy and safety of these all oral therapies for chronic hepatitis C, these outcomes need to be assessed in the real world where patient compliance, comorbidities and other factors can affect the SVR rates. We report here a real life experience from India with DAA based regimes for treatment genotypes 1, 3 and 4 chronic hepatitis C.
A large number of patients diagnosed with hepatitis C (77%) opted for treatment. Our study showed higher rates of SVR in genotypes 1, 3 and 4 when compared to the Phase-3 trials and the real world experiences from the West. The possible reasons for higher SVR could be related to both viral and host related factors. There were a fewer number of patients with HBV coinfection and none with HIV coinfection in our study. A larger number of patients with genotype 1b, which is considered to have a better therapeutic response with DAA therapy could also have contributed to higher rates of response. We also observed a higher prevalence of sub-genotype 3a,
as noted from the neighbouring areas in Pakistan and these patients had an excellent response to treatment. 23 24 High SVR could also be attributed to host factors like a larger number of treatment naïve and non-cirrhotic patients.
The lower cost of sofosbuvir based protocols (as compared to Western world) and fewer side effects have increased the acceptability of therapy in developing nations like India. Our previous real life experience with pegylated interferon and ribavirin
Page 15 of 29 A c c e p t e d M a n u s c r i p t showed a much lower (one-third) acceptance for initiation of treatment and low SVR rates due to poor tolerability (6%) and non response (1%). 25 . In the present cohort of patients treated with DAAs, 77% of the patients diagnosed with hepatitis C infection opted for treatment and the therapy was well tolerated even in difficult to treat groups of patients like those with cirrhosis and past history of treatment failure. There were no major adverse events requiring discontinuation of therapy. Six patients (0.9%) had non response to therapy. None of these had achieved RVR and the duration of therapy in all these patients was 12 weeks (Figure 1) . Extension of therapy to 24
weeks after a failed RVR in these patients may have increased the SVR rate.
Our study also presents the first real world experience of treatment of genotype 4
with SOF/LDV with or without RBV from Asia. SVR 12 rate in this group of patients (including cirrhotics and treatment experienced patients) was 100%. Though the number of patients with genotype 4 was small, these results support the efficacy of these regimens in patients with genotype 4 infection as shown in clinical trials.
The study had a few limitations. It was a single center study. Subtyping into genotype 1a and 1b was not done in 43% of the patients. The number of patients with genotype 4 was small (though expected due to low prevalence of genotype 4 in Asia).
In conclusion, our data show that DAA-based regimens are safe and have a high success rate in the treatment of patients with genotypes 1,3 and 4 HCV infection in real-life setting. This is independent of the liver status and past history of treatment.
The availability of the dual-DAA regimens at low cost or free of cost at some areas Page 16 of 29 A c c e p t e d M a n u s c r i p t under health care schemes, lower rates of major adverse events, ease of oral dosing has lead to increasing acceptability of treatment. Development of comprehensive strategies to improve awareness of hepatitis C, provision of universal screening with confidential testing for all, provision of drugs at low cost and counselling to reduce spread and reinfection in populations at high risk can help us achieve a world free of hepatitis C virus.
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